Zobrazeno 1 - 10
of 780
pro vyhledávání: '"W. Press"'
Autor:
Phuong Vo, Ted A. Gooley, Joseph G. Rajendran, Darrell R. Fisher, Johnnie J. Orozco, Damian J. Green, Ajay K. Gopal, Robyn Haaf, Margaret Nartea, Rainer Storb, Frederick R. Appelbaum, Oliver W. Press, John M. Pagel, Brenda M. Sandmaier
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
Outcomes of patients with persistent high-risk leukemia or myelodysplasia prior to allogeneic hematopoietic cell transplantation are dismal. We therefore conducted a phase I trial evaluating the use of CD45-targeted radiotherapy preceding hematopoiet
Externí odkaz:
https://doaj.org/article/5305b45938ed4d9fbd2343bde3761ae8
Autor:
Monika Pilichowska, Stefania Pittaluga, Judith A. Ferry, Jessica Hemminger, Hong Chang, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Jeremy S. Abramson, Athena Kritharis, Francisco J. Hernandez-Ilizaliturri, Izidore S. Lossos, Oliver W. Press, Timothy S. Fenske, Jonathan W. Friedberg, Julie M. Vose, Kristie A. Blum, Deepa Jagadeesh, Bruce Woda, Gaurav K. Gupta, Randy D. Gascoyne, Elaine S. Jaffe, Andrew M. Evens
Publikováno v:
Blood Advances, Vol 1, Iss 26, Pp 2600-2609 (2017)
Abstract: Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). However, there remains complexity in establishing diagnosis, delineating prognosis, and determining o
Externí odkaz:
https://doaj.org/article/283076fceed14aaba224980a3961f3c7
Autor:
Brian G. Till, Stanley R. Riddell, David G. Maloney, Damian J. Green, Jeffrey K. Rossow, Lihua E. Budde, Barbara Pender, Ajay K. Gopal, Michael C. Jensen, Sang Yun Lee, Philip Olsen, Oliver W. Press, Gregory A. Rufener
CD20 is an attractive immunotherapy target for B-cell non-Hodgkin lymphomas, and adoptive transfer of T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD20 is a promising strategy. A theoretical limitation is that r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce1813c46f07193be5c47a664c6df0b3
https://doi.org/10.1158/2326-6066.c.6548539.v1
https://doi.org/10.1158/2326-6066.c.6548539.v1
Autor:
John M. Pagel, Oliver W. Press, Brenda Sandmaier, Brian G. Till, Ajay K. Gopal, Damian J. Green, K. Dane Wittrup, Kelly D. Orcutt, D. Scott Wilbur, Donald K. Hamlin, Ethan R. Balkin, Darrell R. Fisher, Mark D. Hylarides, Alexandra H. Hernandez, Margaret E. Nartea, Rosario Guel, Shyril O'Steen, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco
Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cb196c04e590eb312858a4d9061fed
https://doi.org/10.1158/1535-7163.c.6542662
https://doi.org/10.1158/1535-7163.c.6542662
Autor:
John M. Pagel, Oliver W. Press, Brenda Sandmaier, Brian G. Till, Ajay K. Gopal, Damian J. Green, K. Dane Wittrup, Kelly D. Orcutt, D. Scott Wilbur, Donald K. Hamlin, Ethan R. Balkin, Darrell R. Fisher, Mark D. Hylarides, Alexandra H. Hernandez, Margaret E. Nartea, Rosario Guel, Shyril O'Steen, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco
Supplementary Materials, Methods and relevant AA sequences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c057d8965675ca7f790ca8236eb48a
https://doi.org/10.1158/1535-7163.22520518.v1
https://doi.org/10.1158/1535-7163.22520518.v1
Autor:
Oliver W. Press, Brian G. Till, Amelia Waltman, Theodore A. Gooley, Mark D. Hylarides, Darrell R. Fisher, Donald K. Hamlin, D. Scott Wilbur, Yukang Lin, Aimee L. Kenoyer, Johnnie J. Orozco, Ajay K. Gopal, Damian J. Green, Shyril O'Steen
Table S1 presents mouse survival data for in vivo experiments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1f8931fda4e9dec0f52f77d94c1a28
https://doi.org/10.1158/0008-5472.22414092.v1
https://doi.org/10.1158/0008-5472.22414092.v1
Autor:
Oliver W. Press, K. Dane Wittrup, D. Scott Wilbur, Kelly D. Orcutt, Shyril O'Steen, Brian G. Till, Johnnie J. Orozco, Theodore A. Gooley, Ajay K. Gopal, Mark D. Hylarides, Aimee L. Kenoyer, Sofia H.L. Frost, Darrell R. Fisher, Donald K. Hamlin, Yukang Lin, Shani L. Frayo, Damian J. Green
Figures including: Supplemental Figure 1- Dose finding pharmacokinetics. Supplemental Figure 2- Dose finding tissue biodistribution. Supplemental Figure 3- body weight over time in a therapy study. Supplemental Figure 4- blood counts over time in a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27fa9ad6c582f79e53958516ac3c2d49
https://doi.org/10.1158/0008-5472.22413027
https://doi.org/10.1158/0008-5472.22413027
Autor:
Oliver W. Press, K. Dane Wittrup, D. Scott Wilbur, Kelly D. Orcutt, Shyril O'Steen, Brian G. Till, Johnnie J. Orozco, Theodore A. Gooley, Ajay K. Gopal, Mark D. Hylarides, Aimee L. Kenoyer, Sofia H.L. Frost, Darrell R. Fisher, Donald K. Hamlin, Yukang Lin, Shani L. Frayo, Damian J. Green
Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dc53f403d5241580b8113781f0a0c07
https://doi.org/10.1158/0008-5472.c.6508593.v1
https://doi.org/10.1158/0008-5472.c.6508593.v1
Autor:
Oliver W. Press, John M. Pagel, Damian J. Green, Ajay K. Gopal, Amanda Axtman, Aimee L. Kenoyer, Franz Buchegger, Mark Hylarides, Nural Orgun, Patrick S. Stayton, D. Scott Wilbur, Yukang Lin, Donald K. Hamlin, Shani M. Frayo, Jaideep Shenoi, Steven I. Park
Purpose: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, “endogenous” biotin can interfere with the effectiveness of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac83bf1161f96c54d74b350d1a496f57
https://doi.org/10.1158/1078-0432.c.6519756
https://doi.org/10.1158/1078-0432.c.6519756
Autor:
Richard I. Fisher, Thomas P. Miller, Shaker R. Dakhil, Bruce D. Cheson, David G. Maloney, Ajay K. Gopal, Catherine Spier, Rita M. Braziel, Mark Kaminski, Myron S. Czuczman, Michael LeBlanc, Jonathan W. Friedberg, Lisa M. Rimsza, Joseph M. Unger, Oliver W. Press
Purpose: There is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial comparing six cycles of CHOP-R (cyclophosphamide–Adriamycin–vincristine–prednisone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a19c0753e0360dd904c46e61974f08c0
https://doi.org/10.1158/1078-0432.c.6521750
https://doi.org/10.1158/1078-0432.c.6521750